Skip to main content
. 2022 Mar 15;12:824511. doi: 10.3389/fonc.2022.824511

Figure 2.

Figure 2

(A) Gender distribution of neurological consequences occurring in European patients treated with at least one ICI and collected from the EudraVigilance database until February 7, 2020. (B) Gender distribution of neurological outcomes collected from EudraVigilance categorized by single ICI treatment. *pembrolizumab/nivolumab/ipilimumab, pembrolizumab/atezolizumab, ipilimumab/pembrolizumab.